id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-3305-0006,FDA,FDA-2016-E-3305,"Determination of Regulatory Review Period for Purposes of Patent
Extension; PROVAYBLUE",Notice,Determinations,2018-11-30T05:00:00Z,2018,11,2018-11-30T05:00:00Z,2019-01-30T04:59:59Z,2019-01-30T02:13:15Z,2018-26035,0,0,0900006483916277
FDA-2016-E-3305-0005,FDA,FDA-2016-E-3305,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T13:12:27Z,,0,0,09000064838eb876
FDA-2016-E-3305-0004,FDA,FDA-2016-E-3305,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,,2018-10-01T13:55:58Z,,0,0,0900006483786656
FDA-2016-E-3305-0003,FDA,FDA-2016-E-3305,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2018-02-06T05:00:00Z,2018,2,2018-02-06T05:00:00Z,,2018-02-06T20:29:25Z,,0,0,0900006482ef444a